CCRL1 抗体 (2nd Cytoplasmic Domain)
Quick Overview for CCRL1 抗体 (2nd Cytoplasmic Domain) (ABIN1732791)
抗原
See all CCRL1 抗体适用
宿主
克隆类型
标记
应用范围
- 
    - 
                                            抗原表位
- 2nd Cytoplasmic Domain
- 
                                            特异性
- Reacts with human CCRL1
- 
                                            交叉反应 (详细)
- BLAST analysis of the peptide immunogen showed no homology with other human proteins.
- 
                                            纯化方法
- Antigen affinity purified
- 
                                            免疫原
- Synthetic 19 amino acid peptide from 2nd cytoplasmic domain of human CCRL1. Percent identity with other species by BLAST analysis: Human (100%), Gorilla (100%), Gibbon (100%), Monkey (84%), Rat (84%), Bovine (84%).
- 
                                            亚型
- IgG
 
- 
                                            
- 
    
- 
    - 
                                            应用备注
- 
                        Working dilution: IHC-P (24 μg/mL - 32 
- 
                                            限制
- 仅限研究用
 
- 
                                            
- 
    - 
                                            浓度
- 1 mg/mL
- 
                                            缓冲液
- PBS, Sodium azide 0.1 %
- 
                                            储存液
- Sodium azide
- 
                                            注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 
                                            储存条件
- 4 °C/-80 °C
- 
                                            储存方法
- Long term: -70°C, Short term: +4°C
 
- 
                                            
- 
    - CCRL1 (Chemokine (C-C Motif) Receptor-Like 1 (CCRL1))
- 
                                            别名
- CCRL1
- 
                                            UniProt
- Q9NPB9
 抗原
- 
                    
 
                                     
                                     
                                    